A carregar...
Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale
Introduction Cytokine release syndrome in COVID-19 is characterized by hyperinflammation, which manifests as acute respiratory distress syndrome (ARDS), multiorgan failure, and high inflammatory parameters. Tocilizumab, an interleukin 6 (IL-6) antagonist has been used in COVID-19 ARDS with conflicti...
Na minha lista:
| Publicado no: | Cureus |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cureus
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7829612/ https://ncbi.nlm.nih.gov/pubmed/33510989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.12290 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|